Overview

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open, exploratory clinical study to evaluate the efficacy of carrelizumab (PD-1) combined with chemotherapy (SOX/XELOX) as neoadjuvant therapy and to observe the changes of tumor immune microenvironment in patients with locally advanced gastric or gastroesophageal junction cancer (T3-4NXM0).
Phase:
Phase 2
Details
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Collaborator:
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Treatments:
Capecitabine
Oxaliplatin